A true multidisciplinary shock team isn’t optional—it’s essential. 🫁 ER 🫀 Interventional 🧠 Critical care 🩺 Heart failure ⚕️ Surgery & ECMO The latest #HFBeat shows how the best teams coordinate care in minutes. 🔗 https://t.co/assj5mS72I @MHBeasleyMD @priyaumapathi

Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation: @NEJM 🥸 Trials at #ACC25 - Dapagliglozin in pts with TAVR! 😱 Summary 👇👇👇👇

NEW! 2025 US guidelines for the management of ACS (STEMI and NSTE-ACS) just released. Intravascular imaging guidance with OCT or IVUS during PCI in ACS is now recommended for left main or complex lesions with a class IA recommendation.

#GuideExtensionTelescoping technique In extreme cases of #CoronaryCalcifications where 1 #GuideExtension is not enough, one of the ways to push support safely to a whole different level is to ADD another #GuideExtensionCatheter @adityadoc1 @evandrofilhobr @timir_paul

Astonishing results from the DanGer Shock Trial presented at #ACC24 and out in @NEJM today. In patients with ST-elevation MI with cardiogenic shock, Impella reduced all-cause mortality (45.8% Impella vs. 58.5% control) at 180 days. Some thoughts on this ground breaking trial:

Exciting to start New Year 2024 with publication of our work on "Artificial Intelligence enabled ECG for diastolic function and filling pressure". Diastolic function by AI-ECG has a similar prognostic value as that of Echo. @drpaulfriedman @MayoClinicCV https://t.co/gP2jxh6kEC

@AlejandroLemor @SarahGorgis @bkolskk @adityadoc1 @AliNsairMD @Allison_Dupont @AGoldsweig @mjlimmd @agtruesdell @NavinKapur4 We implemented the NCSI to provide clinicians a more uniform mechanism for the use of MCS and to help fill the void of inexperience and unfamiliarity regarding MCS. i.e. providing a game plan

Making the Post-Discharge Phase Far Less Vulnerable in HFrEF @SJGreene_md @JavedButler1 @MarcoMetra @ESC_Journals https://t.co/Dk9h3iDoSg

There is a viral disease Where most infections are mild, asymptomatic With a very low fatality rate And large age gradient: kids are even lower risk than adults And less than 1% of kids have any serious complications at all Yup Polio And we vaccinate against it

HFrEF Within 30-60 days of Rx ✅ARNI ⤵️CV☠️HF🏨 42% ✅BB ⤵️☠️25% ✅MRA ⤵️CV☠️HF🏨 37% ✅SGLT2i ⤵️☠️HF🏨urgent visit 58% Unnecessary delays in Rx result in significant harms @SJGreene_md @JavedButler1 @robmentz @DLBHATTMD @MKIttlesonMD @jesse8850 #AHA21

Vaccination impact in Los Angeles County, largest in the US, since beginning of campaign in December thru June 7 437,000 cases: 99.6% in unvaccinated 12,900 hospitalizations: 98.7% in unvaccinated 12,234 deaths: 99.8% in unvaccinated https://t.co/Z8LvehDZXo

Congratulations Joerg and team on your JACC Interventional publication. Important contribution to understanding event rates in cancer patients post intervention/PCI

"Young and healthy people can expect to recover fully and quickly" — Trump, March 11, 2020 The leading causes of death by age. We have no idea about per cent affected by #LongCovid https://t.co/1z5YgPd8Jz by @DLeonhardt

Just published @TheLancet: Effect of vaccine in >23,000 health care workers https://t.co/ohy3VyHM3C Dose response: No vaccine 977 infections; 1 dose 71 infections; 2 doses 9 infections (14|8|4 per 10,000 person-days) "can prevent both symptomatic and asymptomatic infection "

You may have missed a lot of good news about another vaccine today ✓ No CVST or thrombotic events, > 64.5 million doses ✓ 95% protection vs severe infections in extended 6 mo f/u of 900 cases in main trial ✓ Progress for vaccine vs B.1. 351, and kids https://t.co/dvsAE8ItzY

Can anyone suggest wat is this? @krishnamkorde @pramesh0522 @mailtarun07 @DRGAURA44938886 @riyaz_doc

FDA Expanded ARNI use in HFpEF/non-normal EF pts with HF. Will be interesting to see how this impacts practice. #Paragon https://t.co/D7gH1Dsu4m

Most important (heck, almost miraculous) vaccine takeaway: 100% effectiveness at preventing serious illness or death. (ht @ashishkjha)

Smh.

Pt with Medina 1,1,0 distal LM bifurcation. PCI with provisional 1-stent technique - 3.5 mm DES followed by 4.5 mm POT - resulted in high-grade stenosis at origin of LCX. TIMI 3 flow, no symptoms or ECG changes. iFR of LCX performed=0.94. Next steps? Poll to follow.